**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 77473

**Manuscript Type:** MINIREVIEWS

**Oncologic aspects of the decision-making process for surgical approach for colorectal liver metastases progressing during chemotherapy**

Araujo RLC *et al*. Surgery for CRLM progressing during chemotherapy

Raphael L C Araujo, Camila G C Y Carvalho, Carlos T Maeda, Jean Michel Milani, Diogo G Bugano, Pedro Henrique Z de Moraes, Marcelo M Linhares

**Raphael L C Araujo, Carlos T Maeda, Jean Michel Milani, Marcelo M Linhares,** Department of Surgery, Universidade Federal de São Paulo, São Paulo 04024-002, Brazil

**Raphael L C Araujo, Diogo G Bugano, Pedro Henrique Z de Moraes,** Department of Oncology, Hospital Israelita Albert Einstein, São Paulo 05652-900, Brazil

**Raphael L C Araujo, Camila G C Y Carvalho,** Department of Surgical Oncology, Hospital e Maternidade Brasil Rede D'Or São Luiz, Santo André 09030-590, São Paulo, Brazil

**Author contributions:** Araujo RLC contributed to the study conception, data preparation, data interpretation, and writing; Carvalho CGCY contributed to the data preparation, data interpretation, and writing; Maeda CT, Milani JM contributed to the data acquisition, data preparation, and writing; Bugano DG, de Moraes PHZ and Linhares MM contributed to the data interpretation, and critical writing of the paper.

**Corresponding author: Raphael L C Araujo, MD, PhD, Adjunct Professor, Surgical Oncologist,** Department of Surgery, Universidade Federal de São Paulo, Rua Napoleão de Barros, 715 Second Floor Vila Clementino, São Paulo 04024-002, Brazil. raphael.l.c.araujo@gmail.com

**Received:** May 2, 2022

**Revised:** July 27, 2022

**Accepted: August 15, 2022**

**Published online:**

**Abstract**

Colorectal cancer represents the third most diagnosed malignancy in the world. The liver is the main site of metastatic disease, affected in 30% of patients with newly diagnosed disease. Complete resection is considered the only potentially curative treatment for colorectal liver metastasis (CRLM), with a 5-year survival rate ranging from 35% to 58%. However, up to 80% of patients have initially unresectable disease, due to extrahepatic disease or bilobar multiple liver nodules. The availability of increasingly effective systemic chemotherapy has contributed to converting patients with initially unresectable liver metastases to resectable disease, improving long-term outcomes, and accessing tumor biology. In recent years, response to preoperative systemic chemotherapy before liver resection has been established as a major prognostic factor. Some studies have demonstrated that patients with regression of hepatic metastases while on chemotherapy have improved outcomes when compared to patients with stabilization or progression of the disease. Even if disease progression during chemotherapy represents an independent negative prognostic factor, some patients may still benefit from surgery, given the role of this modality as the main treatment with curative intent for patients with CRLM. In selected cases, based on size, the number of lesions, and tumor markers, surgery may be offered despite the less favorable prognosis and as an option for non-chemo responders.

**Key Words:** Colorectal liver metastases; Oncology; Disease progression; Surgery; Liver resection; Hepatectomy

Araujo RLC, Carvalho CGCY, Maeda CT, Milani JM, Bugano DG, de Moraes PHZ, Linhares MM. Oncologic aspects of the decision-making process for surgical approach for colorectal liver metastases progressing during chemotherapy. *World J Gastrointest Surg* 2022; In press

**Core Tip:** The mainstream curative-intent treatment of colorectal liver metastasis (CRLM) is complete surgical resection. Increasingly effective systemic chemotherapy has helped to improve long-term outcomes, downstaging of CRLM, and patient selection for surgery. Disease progression during chemotherapy represents an independent negative prognostic factor. However, in selected cases, based on size, the number of lesions, and tumor markers, surgery may be offered as an option for non-chemo responders. This minireview article aims to explore this open question in the literature using both evidence and meaningful thoughts on this controversial and challenging topic.

**INTRODUCTION**

Colorectal cancer (CRC) represents the third most diagnosed malignancy and the second cause of cancer-related death in the world, with an estimated incidence of 1931590 new cases in 2020[1]. Approximately 30% of patients will present metastases at diagnosis, and 10% to 20% of stage 1-3 diseases will progress to local or distant metastases[2]. Half of the patients with metastatic disease will have liver metastases, which are unresectable in up to 80% of cases due to extrahepatic disease or bilobar multiple liver nodules[2].

Patients with initially resectable colorectal liver metastasis (CRLM) but with either high tumor burden or bad prognostic factors usually go to upfront chemotherapy and then surgery. Complete resection is considered the only potentially curative treatment for CRLM, with 5-year survival rates ranging from 35% to 58%[3]. However, part of these patients will progress during pre-operative chemotherapy, and for this group, the role of resection of CRLM remains controversial and with large discrepancies in the literature. This minireview article aims to address oncologic aspects that drive the decision-making process, in a multidisciplinary manner, to offer surgery for patients with CRLM who are progressing during chemotherapy. Despite the scarcity of literature on the subject, we believe that this specific patient population deserves more individualized evaluation because their inherent condition of progression during systemic chemotherapy has kept them from being included in most of the trials with curative-intent treatment.

**Liver resection for CRLM**

The mainstream curative-intent treatment of CRLM is complete surgical resection. Although metastasectomy has never been tested in a randomized controlled trial, studies have demonstrated long-term survival and cure after this approach[4]. The standard recommended surgical treatment for CRLM is complete macroscopic resection with negative margins (R0 resection). However, complete removal of the macroscopic tumor without safe margins (R1 resection) may be accepted in vascular proximity or multi-nodularity cases. The use of increasingly effective chemotherapy has changed long-term outcomes after R1 resection, with survival similar to that of R0 resection[5].

In 1999, Fong *et al*[6] described the most used Clinical Risk Score (CRS) to predict recurrence after hepatic resection for metastatic CRLM. It was based on five independent prognostic factors: Positive nodal status of the primary tumor, the disease-free interval from identification of the primary tumor to the discovery of liver metastases of < 12 mo, number of metastatic tumors > 1, preoperative carcinoembryonic antigen (CEA) level > 200 ng/mL, and size of the largest tumor > 5 cm. Patients with scores of 0, 1, or 2 had more favorable outcomes compared with scores of 3, 4, or 5[6]. This CRS works as a practical clinical tool helping to select patients for upfront surgery or systemic therapy according to the estimated risks.

Despite the definition of resectability varying from center to center, metastases are usually considered resectable if they can be completely removed (R0 resection) while leaving an adequate functional parenchyma volume[7]. Usually, resectable lesions are those that can be completed removed with a remnant liver representing at least two contiguous segments, granting the patency of inflow and outflow structures, and sparing at least 20% of total liver volume, for healthy and unexposed livers to chemotherapy, or at least 30% for patients who underwent previous chemotherapy[8]. However, up to 70%-80% of patients with CRLM are not initial candidates for hepatic resection[9].

Several strategies have been introduced to the clinical practice to increase the number of patients eligible for curative hepatic resection, including neoadjuvant chemotherapy, two-stage hepatectomies, and portal vein embolization. In 2004, Adam *et al*[10] reported postoperative 5-year survival of patients submitted to conversion therapy is 33% after rescue surgery[10]. This outcome remains a work in progress and has been increasing with the advent of more modern systemic therapy such as triplet therapies and monoclonal antibodies.

**Perioperative chemotherapy in initially resectable patients**

Despite patients undergoing surgical curative-intent treatment, R0 Liver resection, nearly 50%-65% of patients submitted to surgery will relapse within 5 years[11]. Therefore, the use of perioperative systemic chemotherapy has increased over the last decades as an effort to improve long-term outcomes.

Regardless of being associated with an objective response rate of 50%-65%, the survival benefit of perioperative chemotherapy remains controversial[12]. The EPOC clinical trial randomized patients with initially resectable CRLM into preoperative chemotherapy (FOLFOX4) or surgery alone. While no benefit in overall survival (OS) was demonstrated, preoperative chemotherapy significantly increased progression-free survival (PFS) in eligible patients and those with resected CRLM[13]. Based on those findings, the addition of systemic chemotherapy to surgical resection has become the standard of care for CRLM in many centers.

A comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic CRC was conducted at the Memorial Sloan-Kettering Cancer Center. Both OS and recurrence-free survival (RFS) were similar between the groups when adjusted for clinical-pathological factors and CRSs. Therefore, the authors concluded that the timing of additional chemotherapy for resected CRLM was not associated with outcomes[14].

Corroborating those findings, a systematic review, and meta-analysis of chemotherapy for patients with CRLM who underwent curative hepatic resection showed that regardless of timing and based on nonrandomized and randomized data, patients submitted to hepatic resection for CRLM should receive additional chemotherapy, given that this strategy relative increases RFS and OS in 29 and 23%, respectively[15]. Recently, a randomized controlled trial examining the use of adjuvant chemotherapy (modified infusional fluorouracil, leucovorin, and oxaliplatin-mFOLFOX6) in patients with liver-only metastatic CRC was published. Kanemitsu *et al*[16], after a median follow-up of 59.2 mo, demonstrated that adjuvant chemotherapy improved 5-years disease-free survival when compared to hepatectomy alone (49.8% *vs* 38.7%, CI: 0.41-0.92; *P* = 0.006). No significant differences in 5-year OS were detected, 71.2% (95%CI: 61.7-78.8) with adjuvant chemotherapy and 83.1% (95%CI: 74.9-88.9) with hepatectomy alone. Nonetheless, this trial was not designed to detect a difference in OS as a primary endpoint, and indeed, it has not a long enough follow-up to detect this difference, so improvements in OS could not be demonstrated[16].

The benefit of adding new systemic therapies to improve outcomes in patients with resectable CRLM has been tested. The New EPOC was a phase III trial that included patients with resectable exon-2 RAS wild-type metastatic CRC, randomly assigned to receive perioperative chemotherapy, doublet oxaliplatin-based therapy, with or without cetuximab. The incorporation of cetuximab not only correlated with significantly inferior PFS but also with a trend towards decreased OS. Although the addition of cetuximab to chemotherapy may improve outcomes in patients with initially inoperable metastatic disease, its use preoperatively in resectable patients confers a significant disadvantage and should not be a routine[17].

It seems that chemotherapy should be incorporated into the treatment of resectable CRLM, increasing PFS, and possibly OS. However, the best timing for additional chemotherapy remains unclear. Delivering chemotherapy preoperatively may be used as a means of testing tumor biology in vivo, identifying patients who will benefit most from surgery. Recently, response to neoadjuvant chemotherapy has been established as a major prognostic factor once patients with disease stabilization or progression while on chemotherapy seem to have worse outcomes than responders[18]. Other benefits of initial chemotherapy may be the earlier treatment of micrometastatic disease and cytoreduction of the hepatic disease, facilitating surgical resection. On the other hand, oxaliplatin or irinotecan-based neoadjuvant chemotherapy can increase the rates of perioperative morbidity and cause liver toxicity.

Considering symptomatic synchronous tumors, it is suggested to direct the treatment to the primary tumor first, with resection and/or deviation, followed by systemic chemotherapy. For asymptomatic patients with synchronous tumors and those with metachronous hepatic disease, the timing of additional chemotherapy should be guided by the CRS of recurrence, as proposed by Fong *et al*[6]. For potentially resectable patients with a low risk of recurrence (0-2), initial surgery rather than neoadjuvant chemotherapy could be chosen, followed by postoperative chemotherapy. For patients with a high risk of recurrence (3-5), neoadjuvant chemotherapy is the preferred approach[3]. Pre-operative chemotherapy, on the other hand, is an important resource for liver parenchyma sparing in patients who require extended hepatectomy, regardless of whether they have a high or low CRS. Perhaps this action prevents postoperative liver dysfunction and increases the chances of a preserved clinical performance when undergoing postoperative chemotherapy or re-hepatectomy when indicated.

**Perioperative chemotherapy in initially unresectable patients**

For patients with initially unresectable or critically located colorectal liver metastases, upfront chemotherapy represents an appropriate option as conversion therapy. However, the likelihood of downstaging a patient to the point of resectability seems to be below, on the order of 5% to 15%, even in the hands of aggressive surgeons[19].

A regime leading to high response rates and a large tumor shrinkage is recommended. Although there are uncertainties surrounding the best combination to use, it seems that for RAS wild-type disease a cytotoxic doublet in association with an anti-epidermal growth factor receptor (EGFR) offers the best benefit-risk/ratio. For patients with RAS-mutant disease, the preference is for a cytotoxic doublet plus bevacizumab or FOLFOXIRI plus bevacizumab[20].

A meta-analysis assessing the effect of cetuximab and panitumumab in patients with liver-limited initially unresectable CRLM showed that the addition of anti-EGFR increased the R0 resection rate by 60% and reduced the risk of progression by 32%[21]. Considering non-liver limited disease, the CRYSTAL trial demonstrated that FOLFIRI plus anti-EGFR as first-line treatment was beneficial when compared to FOLFIRI alone, especially for the subgroup of wild-type K-RAS[22]. The FOLFIRI plus anti-EGFR *vs* FOLFIRI plus anti-vascular endothelial growth factor (VEGF) for the non-liver limited disease was addressed in the FIRE-3 trial and despite neither difference in objective response nor PFS being identified, FOLFIRI plus anti-EGFR achieve longer OS for patients with wild-type KRAS (33 *vs* 25 mo, *P* = 0.017)[23,24]. However, in a posthoc analysis of this study population, after a centralized analysis of radiological response, FOLFIRI plus anti-EGFR demonstrated better response outcomes than FOLFIRI plus anti-VGFR[23,24]. Furthermore, Tejpar *et al*[25] investigated the primary tumor locations, whether right-sided (from the appendix to the transverse colon) or left-sided (from the splenic flexure to the rectum), in patients with wild-type RAS from both CRYSTAL and FIRE-3[25]. The data suggested that adding anti-EGFR to patients with wild-type RAS right-sided tumors had no benefit; contrary, the data showed that patients with left-sided tumors had better objective response rates, PFS and OS, which seems to be useful for this subgroup of patients, particularly those with symptomatic primary tumors or high tumor burden of CRLM.

Regarding anti-VGFR action, Xu *et al*[26] demonstrated in a systematic review and metanalysis that Bevacizumab-based combination therapies for patients with advanced mCRC show significant higher objective response rates [risk ratios (RR): 1.40], PFS [hazard ratio (HR): 0.64], and OS (HR: 0.82) values when compared than monotherapy. Regrettably, combined anti-VGEF therapies also increase the risk of grade 3/4 treatment-related toxicity (RR: 1.27) when compared to monotherapy[26]. Among the anti-VEGF combined therapies, capecitabine use is associated with a higher risk of grade 3/4 adverse effects (RR: 1.89 *vs* 1.12) than IFL[26].

**Evaluation of response to preoperative chemotherapy**

The Response Evaluation Criteria in Solid Tumors is the recommended method of assessing objective response to preoperative chemotherapy in most clinical trials. The total tumor burden is evaluated by selecting up to five target lesions and calculating the average diameter change based on imaging studies. A reduction of at least 30% is classified as a response and an increase of at least 20% as progression[27].

**Role of surgery in patients progressing while on chemotherapy**

The role of surgery in patients with CRLM progressing while on systemic chemotherapy remains controversial. A summary of the major publications addressing this subject is represented in Table 1.

Allen *et al*[28] evaluated patients with synchronous colorectal liver metastases treated between January 1995 and January 2000. Patients who received preoperative chemotherapy, as a group, had similar OS compared to those submitted to surgery upfront. However, the subgroup of patients with diseases that did not progress while on chemotherapy showed significantly improved survival[28].

Similar results were demonstrated by Adam *et al*[29] in a retrospective analysis of 131 patients submitted to liver resection for CRLM after systemic chemotherapy. In this group, patients could achieve long-term survival after hepatic resection if the disease was controlled by chemotherapy before surgery. However, tumor progression before the operation conferred a poor outcome, even after potentially curative surgery[29].

Neumann *et al*[2] evaluated 160 patients exposed to preoperative chemotherapy, followed by liver resection for CRLM. Factors associated with poor outcomes were noncurative resection, CEA levels > 200 ng/dL, tumor grading, size of largest tumor > 5cm, and the number of metastases. Controversially, tumor progression while on chemotherapy did not influence long-term survival[2]. Those findings are supported by a retrospective study by Gallagher *et al*[30], that found no difference in survival among the three response groups after chemotherapy[30].

A retrospective analysis of patients with hepatic resection of CRLM following second-line chemotherapy was conducted by Brouquet *et al*[31] The regime proved to be feasible and associated with modest survival benefits, representing a viable option in patients with advanced CRLM[31]. Similarly, Adam *et al*[9] found that selected patients submitted to hepatic resection of CRLM after second-line preoperative chemotherapy could have comparable outcomes to patients resected after first-line chemotherapy. In this scenario, independent predictive factors of worse prognosis were positive primary lymph nodes, extrahepatic disease, tumor progression on second-line therapy, and R2 resection[9].

For patients with extensive bilobar disease, selection based on response to pre-hepatectomy chemotherapy seems to be extremely important before planning a two-stage hepatectomy (TSH). Giuliante *et al*[7] found that tumor progression while on preoperative chemotherapy significantly increased the risk of failure to complete the second stage. However, for patients who completed the TSH, long-term outcomes were similar to those reported for patients following a single-stage hepatectomy[7]. In this context, Jouffret *et al*[32] showed that resectable hepatic disease progression in the future remnant liver after portal vein embolization should not be considered a contraindication for second stage hepatectomy[32]. Vigano *et al*[33] reported a series of 128 patients with disease response or stabilization while on preoperative chemotherapy. Early progression of the disease between the end of chemotherapy and liver resection was reported in approximately 15% of patients and was associated with extremely poor survival[33].

Additionally, caution is necessary for patients in the setting of preoperative use of Anti-VGEF since they have a higher risk of treatment-related complications such as hemorrhage, hypertension, neutropenia, stroke, GI perforation, fistula formation and wound healing complications[34]. Thus, it has been recommended an interval of at least 6 wk between the last dose of bevacizumab and elective surgery to mitigate the risk of complications. Nevertheless, its postoperative use should be delayed at least 6 to 8 wk after surgery[34].

**CONCLUSION**

Complete surgical resection remains the only potentially curative treatment for colorectal liver metastases. In this context, several strategies have been introduced to the clinical practice to increase the number of patients eligible for curative hepatic resection, including preoperative chemotherapy, portal vein embolization, two-stage hepatectomies, and association of ablative techniques. In recent years, response to preoperative systemic chemotherapy before liver resection has been established as a major prognostic factor. It seems that progression while on chemotherapy confers a worse prognosis than disease response or stabilization[28,29].

Although the role of surgery in patients progressing while on chemotherapy remains controversial, some patients may still benefit from surgery in this scenario, given the role of this modality as the mainstream curative-intent treatment for patients with CRLM. In selected cases, based on size, the number of lesions, and tumor markers, surgery may be offered despite the less favorable prognosis and as an option for non-chemo responders.

**REFERENCES**

1 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

2 **Neumann UP**, Thelen A, Röcken C, Seehofer D, Bahra M, Riess H, Jonas S, Schmeding M, Pratschke J, Bova R, Neuhaus P. Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases. *Surgery* 2009; **146**: 52-59 [PMID: 19541010 DOI: 10.1016/j.surg.2009.02.004]

3 **Araujo RL**, Riechelmann RP, Fong Y. Patient selection for the surgical treatment of resectable colorectal liver metastases. *J Surg Oncol* 2017; **115**: 213-220 [PMID: 27778357 DOI: 10.1002/jso.24482]

4 **Tomlinson JS**, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. *J Clin Oncol* 2007; **25**: 4575-4580 [PMID: 17925551 DOI: 10.1200/JCO.2007.11.0833]

5 **de Haas RJ**, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? *Ann Surg* 2008; **248**: 626-637 [PMID: 18936576 DOI: 10.1097/SLA.0b013e31818a07f1]

6 **Fong Y**, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg* 1999; **230**: 309-18; discussion 318-21 [PMID: 10493478 DOI: 10.1097/00000658-199909000-00004]

7 **Giuliante F**, Ardito F, Ferrero A, Aldrighetti L, Ercolani G, Grande G, Ratti F, Giovannini I, Federico B, Pinna AD, Capussotti L, Nuzzo G. Tumor progression during preoperative chemotherapy predicts failure to complete 2-stage hepatectomy for colorectal liver metastases: results of an Italian multicenter analysis of 130 patients. *J Am Coll Surg* 2014; **219**: 285-294 [PMID: 24933714 DOI: 10.1016/j.jamcollsurg.2014.01.063]

8 **Charnsangavej C**, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. *Ann Surg Oncol* 2006; **13**: 1261-1268 [PMID: 16947009 DOI: 10.1245/s10434-006-9023-y]

9 **Adam R**, Yi B, Innominato PF, Barroso E, Laurent C, Giuliante F, Capussotti L, Lapointe R, Regimbeau JM, Lopez-Ben S, Isoniemi H, Hubert C, Lin JK, Gruenberger T, Elias D, Skipenko OG, Guglielmi A; LiverMetSurvey International Contributing Centers. Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. *Eur J Cancer* 2017; **78**: 7-15 [PMID: 28407529 DOI: 10.1016/j.ejca.2017.03.009]

10 **Adam R**, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. *Ann Surg* 2004; **240**: 644-57; discussion 657-8 [PMID: 15383792 DOI: 10.1097/01.sla.0000141198.92114.f6]

11 **Viganò L**, Russolillo N, Ferrero A, Langella S, Sperti E, Capussotti L. Evolution of long-term outcome of liver resection for colorectal metastases: analysis of actual 5-year survival rates over two decades. *Ann Surg Oncol* 2012; **19**: 2035-2044 [PMID: 22219066 DOI: 10.1245/s10434-011-2186-1]

12 **Ciliberto D**, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. *Oncol Rep* 2012; **27**: 1849-1856 [PMID: 22446591 DOI: 10.3892/or.2012.1740]

13 **Nordlinger B**, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet* 2008; **371**: 1007-1016 [PMID: 18358928 DOI: 10.1016/S0140-6736(08)60455-9]

14 **Araujo R**, Gonen M, Allen P, Blumgart L, DeMatteo R, Fong Y, Kemeny N, Jarnagin W, D'Angelica M. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. *Ann Surg Oncol* 2013; **20**: 4312-4321 [PMID: 23897009 DOI: 10.1245/s10434-013-3162-8]

15 **Araujo RL**, Gönen M, Herman P. Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: systematic review and meta-analysis. *Ann Surg Oncol* 2015; **22**: 3070-3078 [PMID: 25586244 DOI: 10.1245/s10434-014-4354-6]

16 **Kanemitsu Y**, Shimizu Y, Mizusawa J, Inaba Y, Hamaguchi T, Shida D, Ohue M, Komori K, Shiomi A, Shiozawa M, Watanabe J, Suto T, Kinugasa Y, Takii Y, Bando H, Kobatake T, Inomata M, Shimada Y, Katayama H, Fukuda H; JCOG Colorectal Cancer Study Group. Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial. *J Clin Oncol* 2021; **39**: 3789-3799 [PMID: 34520230 DOI: 10.1200/JCO.21.01032]

17 **Bridgewater JA**, Pugh SA, Maishman T, Eminton Z, Mellor J, Whitehead A, Stanton L, Radford M, Corkhill A, Griffiths GO, Falk S, Valle JW, O'Reilly D, Siriwardena AK, Hornbuckle J, Rees M, Iveson TJ, Hickish T, Garden OJ, Cunningham D, Maughan TS, Primrose JN; New EPOC investigators. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. *Lancet Oncol* 2020; **21**: 398-411 [PMID: 32014119 DOI: 10.1016/S1470-2045(19)30798-3]

18 **Tamandl D**, Gruenberger B, Herberger B, Kaczirek K, Gruenberger T. Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients. *J Surg Oncol* 2009; **100**: 364-371 [PMID: 19235181 DOI: 10.1002/jso.21259]

19 **Adam R**, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? *J Clin Oncol* 2009; **27**: 1829-1835 [PMID: 19273699 DOI: 10.1200/JCO.2008.19.9273]

20 **Van Cutsem E**, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Ann Oncol* 2016; **27**: 1386-1422 [PMID: 27380959 DOI: 10.1093/annonc/mdw235]

21 **Petrelli F**, Barni S; Anti-EGFR agents for liver metastases. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. *Int J Colorectal Dis* 2012; **27**: 997-1004 [PMID: 22358385 DOI: 10.1007/s00384-012-1438-2]

22 **Van Cutsem E**, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009; **360**: 1408-1417 [PMID: 19339720 DOI: 10.1056/NEJMoa0805019]

23 **Heinemann V**, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2014; **15**: 1065-1075 [PMID: 25088940 DOI: 10.1016/S1470-2045(14)70330-4]

24 **Stintzing S**, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V; FIRE-3 investigators. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. *Lancet Oncol* 2016; **17**: 1426-1434 [PMID: 27575024 DOI: 10.1016/S1470-2045(16)30269-8]

25 **Tejpar S**, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ, Heinemann V. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. *JAMA Oncol* 2017; **3**: 194-201 [PMID: 27722750 DOI: 10.1001/jamaoncol.2016.3797]

26 **Xu R**, Xu C, Liu C, Cui C, Zhu J. Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer. *Onco Targets Ther* 2018; **11**: 8605-8621 [PMID: 30584320 DOI: 10.2147/OTT.S171724]

27 **Blazer DG 3rd**, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. *J Clin Oncol* 2008; **26**: 5344-5351 [PMID: 18936472 DOI: 10.1200/JCO.2008.17.5299]

28 **Allen PJ**, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. *J Gastrointest Surg* 2003; **7**: 109-117 [PMID: 12559192 DOI: 10.1016/S1091-255X(02)00121-X]

29 **Adam R**, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? *Ann Surg* 2004; **240**: 1052-61; discussion 1061-4 [PMID: 15570210 DOI: 10.1097/01.sla.0000145964.08365.01]

30 **Gallagher DJ**, Zheng J, Capanu M, Haviland D, Paty P, Dematteo RP, D'Angelica M, Fong Y, Jarnagin WR, Allen PJ, Kemeny N. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. *Ann Surg Oncol* 2009; **16**: 1844-1851 [PMID: 19224284 DOI: 10.1245/s10434-009-0348-1]

31 **Brouquet A**, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? *Cancer* 2011; **117**: 4484-4492 [PMID: 21446046 DOI: 10.1002/cncr.26036]

32 **Jouffret L**, Ewald J, Marchese U, Garnier J, Gilabert M, Mokart D, Piana G, Delpero JR, Turrini O. Is progression in the future liver remnant a contraindication for second-stage hepatectomy? *HPB (Oxford)* 2019; **21**: 1478-1484 [PMID: 30962135 DOI: 10.1016/j.hpb.2019.03.357]

33 **Vigano L**, Darwish SS, Rimassa L, Cimino M, Carnaghi C, Donadon M, Procopio F, Personeni N, Del Fabbro D, Santoro A, Torzilli G. Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? *Ann Surg Oncol* 2018; **25**: 1676-1685 [PMID: 29488188 DOI: 10.1245/s10434-018-6387-8]

34 **Benson AB**, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021; **19**: 329-359 [PMID: 33724754 DOI: 10.6004/jnccn.2021.0012]

35 **de Haas RJ**, Wicherts DA, Flores E, Ducreux M, Lévi F, Paule B, Azoulay D, Castaing D, Lemoine A, Adam R. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. *Ann Surg Oncol* 2010; **17**: 1010-1023 [PMID: 20052553 DOI: 10.1245/s10434-009-0887-5]

36 **Pugh SA**, Bowers M, Ball A, Falk S, Finch-Jones M, Valle JW, O'Reilly DA, Siriwardena AK, Hornbuckle J, Rees M, Rees C, Iveson T, Hickish T, Maishman T, Stanton L, Dixon E, Corkhill A, Radford M, Garden OJ, Cunningham D, Maughan TS, Bridgewater JA, Primrose JN. Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. *Br J Cancer* 2016; **115**: 420-424 [PMID: 27434036 DOI: 10.1038/bjc.2016.208]

37 **Lim E**, Wiggans MG, Shahtahmassebi G, Aroori S, Bowles MJ, Briggs CD, Stell DA. Rebound growth of hepatic colorectal metastases after neo-adjuvant chemotherapy: effect on survival after resection. *HPB (Oxford)* 2016; **18**: 586-592 [PMID: 27346139 DOI: 10.1016/j.hpb.2016.04.006]

38 **Imai K**, Allard MA, Benitez CC, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Bismuth H, Baba H, Adam R. Early Recurrence After Hepatectomy for Colorectal Liver Metastases: What Optimal Definition and What Predictive Factors? *Oncologist* 2016; **21**: 887-894 [PMID: 27125753 DOI: 10.1634/theoncologist.2015-0468]

39 **Ruzzenente A**, Bagante F, Ratti F, Beal EW, Alexandrescu S, Merath K, Makris EA, Poultsides GA, Margonis GA, Weiss MJ, Popescu I, Aldrighetti L, Guglielmi A, Pawlik TM. Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases. *HPB (Oxford)* 2019; **21**: 1230-1239 [PMID: 30792047 DOI: 10.1016/j.hpb.2019.01.014]

40 **Brunsell TH**, Cengija V, Sveen A, Bjørnbeth BA, Røsok BI, Brudvik KW, Guren MG, Lothe RA, Abildgaard A, Nesbakken A. Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. *Eur J Surg Oncol* 2019; **45**: 2340-2346 [PMID: 31350075 DOI: 10.1016/j.ejso.2019.07.017]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** Society for Surgery of the Alimentary Tract; American Hepato-Pancreato-Biliary Association; International Hepato-Pancreato-Biliary Association; International Laparoscopic Liver Society.

**Peer-review started:** May 2, 2022

**First decision:** July 14, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Brazil

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Elshimi E, Egypt; Mukthinuthalapati VVPK, United States; Wang LM, China **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Table 1 Study characteristics according to the type of preoperative chemotherapy, type of response, overall and disease-free survivals of patients who underwent curative-intent treatment hepatectomies for colorectal liver metastases**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | N1 (total) | N (surgery) | Age2 (yr) | Median FU (mo) | Preoperative chemotherapy | R0 (%) | Preoperative chemotherapy response (%) | Median OS (mo) | 1-yr OS (%) | 3-yr OS (%) | 5-yr OS (%) | 1-yr DFS (%) | 3-yr DFS (%) | 5-yr DFS (%) |
| Allen *et al*[28], 2003  | 106 | 52 | 59 | 30 | 5-FU | 82.6 | R: 12 (26); S: 17 (37); P: 17 (37) |  |  |  |  |  |  | RS: 0.87; P: 0.38 |
| Adam *et al*[29], 2004 | 131 | 131 | 59.5 (32-78) | 33.1 | 5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan | 90 | R: 58 (44); S: 39 (30); P: 34 (36) | O: 30 | R: 0.95; S: 0.92; P: 0.63 | R: 0.55; S: 0.44; P: 0.12 | R: 0.37; S: 0.3; P: 0.08 | R: 0.52; S: 0.33; P: 0.23 | R: 0.32; S: 0.23 P: 0.07 | R: 0.21; S: 0.17; P: 0.38 |
| Neumann *et al*[2], 2009 | 160 | 160 | R: 59 (35-77); S: 60 (35-73); P: 60 (36-78) | 28.8 | 5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan/5-FU + Oxaliplatin + Irinotecan + antiEGFR or antiVEGF | 72.5 | R: 44 (27.5); S: 20 (12.5) P: 90 (60) | R: 37.2; S: 44.4; P: 38.1 | O: 0.88 | O: 0.53 | R: 0.34; S: 0.44; P: 0.36 |  |  |  |
| Gallagher *et al*[30], 2009  | 111 | 111 | 61 (27-85) | 63 | 5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/Others | 84.6 | R: 47 (42.3); S: 52 (47); P: 18 (16) | R: 58; S: 65; P: 61 |  |  | R: 0.5; S: 0.51; P: 0.61 |  |  |  |
| Tamandl *et al*[18], 2009  | 244 | 29 | 73.1 (70.1-83) | 34 | 5-FU/Capecitabine |  | R: 13 (44); S: 7 (24) P: 90 (31) |  |  |  | R: 0.64; S: 0.36; P: 0 |  |  |  |
| de Haas *et al*[35], 2010  | 119 | 119 | 61 (51-71) | 34 | 5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/Others | 59.6 | R: 72 (60); S: 28 (24); P: 19 (16) | R: 34; S: 32; P: 20 |  | R: 0.42; S: 0.46; P: 0.36 | R: 0.29; S: 0.28; P: 0.07 |  | R: 0.09; S: 0.09; P: 0.07 |  |
| Brouquet *et al*[31], 2011 | 60 | 60 | 59 (48-70) | 32 | 5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/5-FU + Oxaliplatin or Irinotecan + antiEGFR or antiVEGF | 80 | R: 22 (37); S: 22 (37); P: 16 (27) | R: 41.7; S: 23; P: 15.9 | O: 0.83 | O: 0.41 |  | O: 0.37 | O: 0.11 |  |
| Giuliante *et al*[7], 2014 | 130 | 113 | 58.6 (36-81) | 19 | Oxaliplatin-based/Irinotecan-based/Oxaliplatin + Irinotecan-based/associated antiEGFR/associated antiVEGF | 76.1 | P: 67 (61.5); R: 36 (32.1); P: 7 (6.35) | O: 43 |  |  | O: 0.32 |  |  |  |
| Pugh *et al*[36], 2016  | 110 | 63 | CA: 65; CC: 64 | CA: 14.5; CC: 14.2 | CAPOX/Oxaliplatin-MdG/Irinitecan-MdG/CAPOX + Cetuximab/Oxaliplatin-MdG + cetuximab/Irinitecan-MdG + cetuximab | 100 | O: 63 (100) | CA: 29; CC: 19.9 |  |  |  |  |  |  |
| Lim *el al*[37], 2016  | 155 | 146 | 65 (33-83) | 36 | 5-FU/Capecitabine/5-FU + Oxaliplatin/5-FU + Irinotecan | 85.6 | R: 72 (46.5); S: 48 (31); P: 26 (16.8) |  |  |  |  |  |  |  |
| Imai *et al*[38], 2016  | 846 | 691 | 61 (28-89) | 44.2 | 5-FU/5-FU + Oxaliplatin/5-FU + Irinotecan/ + antiEGFR or -antiVEGF or Panitumumab | 34.1 | RS: 501(72.5); P: 46 (6.6) |  |  | O: 64.7 | O: 49.6 |  | O: 30.1 | O: 19.1 |
| Adam *et al*[9], 2017  | 6415 | 6415 | G1: 61.6; G2: 61.4 | 30.1 | 5-FU + Oxaliplatin/5FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan/5-FU + Oxaliplatin + Irinotecan/ + antiEGFR or -antiVEGF or Panitumumab |  | R: 4710 (73.4); S: 1289 (20.1); P: 416 (6.5) | G1: 58.9; G2: 58.6 |  | G1: 71; G2: 76 | G1: 49; G2: 49 |  | G1: 32; G2: 27 | G1: 23; G2: 15 |
| Vigano *et al*[33], 2018  | 128 | 128 | RS: 61; P: 62 | 30 | 5-FU + Oxaliplatin/5FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan/ + antiEGFR or -antiVEGF or Panitumumab |  | RS: 96 (75); P: 32 (25) |  |  | RS: 52.4; P: 0.23 |  |  | RS: 21.6; P: 6.3 |  |
| Ruzzenente *et al*[39], 2019  | 784 | 784 | 59.4 (51.3-67.8) | - | 5-FU + Oxaliplatin/5FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan/ + antiEGFR or -antiVEGF or Panitumumab |  | RS: 405 (51.6); P: 314 (40.1) |  |  |  | RS: 51.6; P: 40.1 |  |  |  |
| Brunsell *et al*[40], 2019  | 142 | 142 | 67 (21-80) | 37 | 5-FU + Oxaliplatin/5FU + Irinotecan/5-FU + Oxaliplatin + Irinotecan/+ antiEGFR or -antiVEGF or Panitumumab | 37.8 | R: 66 (46.5); S: 63 (44.4); P: 13 (9.1) | R: > 60; S: 47; P: 33 |  |  |  |  |  |  |

1Total *per* study.

2Median (range) or mean plus standard deviation as described by the authors.

FU: Follow-up; 5-FU: 5-fluorouracil; R: Disease response group; S: Stable disease group; P: Progression disease group; RS: Response and stable disease group; O: Overall; OS: Overall Survival; DFS: Disease-Free Survival; MdG: Modified de Gramont; CA: Chemotherapy alone group; CC: Chemotherapy plus cetuximab group; G1: Resection after first-line chemotherapy group; G2: Resection after second-line chemotherapy group.